NEW YORK, June 4, 2026, 04:14 (EDT)
- Artiva ended Wednesday at $6.97, up 1.5% ahead of the Jefferies healthcare conference spot Thursday.
- EULAR data coming this week is in focus for investors looking at AlloNK, Artiva’s off-the-shelf NK cell therapy for autoimmune disease.
- The stock is still a small-cap biotech risk. Early clinical data, timing around regulators, and rival cell-therapy names all factor in.
Artiva Biotherapeutics shares traded up on Wednesday, moving against the Nasdaq’s drop, with traders focused on the company’s spot at the Jefferies healthcare event and new attention for its AlloNK autoimmune program. Shares last changed hands at $6.97, up 10 cents, or 1.5%. The Nasdaq Composite was down 0.9%.
Artiva is set to join a fireside chat at the Jefferies Global Healthcare Conference in New York at 9:20 a.m. EDT on Thursday. That appearance lands as the European Alliance of Associations for Rheumatology meeting is happening in London from June 3 to June 6.
For Artiva, that’s an active window right now. The market isn’t valuing an approved product. It’s betting on whether AlloNK can stay credible as a lower-cost, more scalable cell therapy for autoimmune disease. Allogeneic means donor cells, not the patient’s. NK cells refer to natural killer immune cells. CAR T-cell therapy tends to use engineered T cells, usually made from the patient’s own cells.
Artiva said EULAR is set to feature five AlloNK abstracts, with a late-breaking oral session Saturday focused on 31 patients with rheumatologic diseases. An oral talk on severe Sjögren disease was slated for Wednesday. The company plans a webcast June 8 with Paul Emery, a rheumatology professor from the University of Leeds, to go over the abstracts.
The stock remains far from its 52-week high of $14.53, despite rebounding off its 52-week low of $1.47. Shares closed Wednesday at $6.97, according to Google Finance, after trading between $6.71 and $7.44. The company’s market cap came in near $339 million.
Artiva is focusing on rheumatoid arthritis. In May, the company said five out of seven patients with refractory RA showed an ACR50 response after six months in its Phase 2a basket study. The ACR50 benchmark means those patients had at least a 50% improvement in symptoms by the American College of Rheumatology criteria.
Chief Executive Fred Aslan said late-stage testing is “a new chapter” for Artiva. Stanley Cohen, adjunct professor at University of Texas Southwestern Medical School, said he was “encouraged by the magnitude and consistency” of early improvements. Guillermo Valenzuela, medical director at Integral Rheumatology & Immunology Specialists, said he saw “meaningful improvements” in a lot of refractory patients. Artivabio
Artiva says it has FDA alignment to launch a single Phase 3 randomized trial with around 150 refractory RA patients, testing AlloNK plus rituximab against rituximab alone. The company plans to start the trial in the second half of 2026 and aims to report primary efficacy data in the second half of 2028. If the data support it, a biologics license application could follow in 2029.
Artiva’s cash draw is in focus. A May 8 SEC filing put the company’s cash, cash equivalents, and investments at $86.8 million as of March 31, enough to last into Q2 2027. The company then sold $300 million of stock and pre-funded warrants at $11.52 per share in an underwritten deal, locking in extra money but also bringing dilution into the story.
Rivals are also bringing data to the meeting. On Wednesday, Kyverna said updated EULAR results for its miv-cel CAR T in tough-to-treat RA showed strong B-cell depletion. Most patients in the six-person Phase 1 group reached ACR70 by week 36. Cabaletta Bio gave new EULAR data on rese-cel in several autoimmune diseases, including myositis, lupus, and systemic sclerosis.
The risk for Artiva is the data are early. Cross-trial comparisons are tricky. The company has already said that later clinical results might not match the interim numbers and pooling data from different trials may not be apples to apples. Artiva also said the FDA could give feedback that doesn’t line up with what management expects after talking with regulators. If EULAR isn’t positive or Phase 3 gets pushed back, or if safety turns into a bigger worry—or just if funding tightens up—shares could run into trouble again.
